|Back Zoom + Zoom -|
FOSUN PHARMA (02196.HK), BioNTech Start COVID-19 Vaccine Trial in China
FOSUN PHARMA (02196.HK) and BioNTech announced that the first 72 participants have already been dosed with BNT162b1 following IND approval by the Chinese regulatory authority, National Medical Products Administration (NMPA).
FOSUN PHARMA and BioNTech are jointly developing the COVID-19 vaccine candidate in China. The trial is part of BioNTech’s global development program aimed at supporting a global supply upon regulatory approval.
AAStocks Financial News
Web Site: www.aastocks.com